<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10206284</article-id><article-id pub-id-type="pmc">2362816</article-id><article-id pub-id-type="pii">6690275</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690275</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Prognostic value of DNA flow cytometry in stomach cancer: a 5-year prospective study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lee</surname><given-names>K H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>J S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>J H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>S W</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Suh</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>W K</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>S-H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Min</surname><given-names>Y I</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>B S</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>K C</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>M S</given-names></name><xref ref-type="aff" rid="aff1">3</xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>H S</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><aff id="aff1">Department of MedicineGeneral SurgeryPreventive Medicine, University of Ulsan, College of Medicine, Asan Medical Center, 388-1 Poongnapdong, Songpa-ku, Seoul, 138-736, Korea</aff><aff id="aff4">Department of Medicine, Catholic University Medical College, St. Mary Hospital, Seoul, 150-713, Korea</aff></contrib-group><pub-date pub-type="ppub"><month>4</month><year>1999</year></pub-date><volume>79</volume><issue>11-12</issue><fpage>1727</fpage><lpage>1735</lpage><history><date date-type="received"><day>03</day><month>06</month><year>1998</year></date><date date-type="rev-recd"><day>05</day><month>10</month><year>1998</year></date><date date-type="accepted"><day>14</day><month>10</month><year>1998</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 1999 Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>The role of DNA flow cytometry in the prediction of prognosis for patients with stomach cancer remains to be defined. Thus we studied prospectively the role of DNA flow cytometry as a prognosis indicator in stomach cancer patients in a high-incidence area. Between November 1990 and December 1992, primary stomach cancer tissues were obtained from the surgical specimens from 217 patients (148 male, 69 female). DNA flow cytometric analyses of DNA ploidy and S-phase fraction were performed and the results were correlated with patient survival. The median age of the patients was 55 years (range 24&#x02013;78). Aneuploid cell population was found in 114 of 217 samples (53&#x00025;). Tumour S-phase fraction was obtained in 96 of 103 diploid tumours (93&#x00025;) and 61 of 114 aneuploid tumours (54&#x00025;). After median follow-up of 66.1 months, the patients with tumours with an S-phase fraction over 17&#x00025; had significantly worse survival rates than patients with tumours with S-phase fractions of lower than 8&#x00025; or 8&#x02013;17&#x00025; (45&#x00025; vs 59&#x00025; and 63&#x00025; of patients surviving, <italic>P</italic> = 0.007). Tumour ploidy status did not correlate with patient survival. Multivariate analyses showed that the TNM stage remained the most important prognostic indicator. The tumour S-phase fraction was also an independent prognostic indicator (relative risk 2.300, 95&#x00025; CI, 1.252&#x02013;4.223). Tumour S-phase fraction obtained by DNA flow cytometry is an independent prognostic indicator for the survival of the patients with stomach cancer. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>stomach cancer</kwd><kwd>DNA flow cytometry</kwd><kwd>DNA ploidy</kwd><kwd>S-phase fraction</kwd><kwd>prognostic factor</kwd></kwd-group></article-meta></front></article>
